Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

ARVN

Arvinas (ARVN)

Arvinas Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ARVN
일자시간출처헤드라인심볼기업
2024/05/1005:42GlobeNewswire Inc.Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressNASDAQ:ARVNArvinas Inc
2024/05/0805:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARVNArvinas Inc
2024/05/0720:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
2024/05/0720:00GlobeNewswire Inc.Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
2024/05/0220:00GlobeNewswire Inc.Arvinas to Present at Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
2024/04/2505:30GlobeNewswire Inc.Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerNASDAQ:ARVNArvinas Inc
2024/04/1120:00GlobeNewswire Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerNASDAQ:ARVNArvinas Inc
2024/03/1905:40GlobeNewswire Inc.Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerNASDAQ:ARVNArvinas Inc
2024/03/0421:00GlobeNewswire Inc.Arvinas to Participate in Upcoming Investor ConferencesNASDAQ:ARVNArvinas Inc
2024/02/2808:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
2024/02/2808:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
2024/02/2808:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
2024/02/2808:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
2024/02/2806:46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ARVNArvinas Inc
2024/02/2721:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
2024/02/2721:00GlobeNewswire Inc.Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ARVNArvinas Inc
2024/02/2106:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
2024/02/2106:05GlobeNewswire Inc.Arvinas Announces Chief Financial Officer TransitionNASDAQ:ARVNArvinas Inc
2024/02/2021:00GlobeNewswire Inc.Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative DiseaseNASDAQ:ARVNArvinas Inc
2024/02/1422:00GlobeNewswire Inc.Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast CancerNASDAQ:ARVNArvinas Inc
2024/02/1410:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARVNArvinas Inc
2024/02/0620:45GlobeNewswire Inc.Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast CancerNASDAQ:ARVNArvinas Inc
2024/02/0206:30GlobeNewswire Inc.Arvinas to Present at 6th Annual Guggenheim Biotechnology ConferenceNASDAQ:ARVNArvinas Inc
2024/01/1707:01GlobeNewswire Inc.Arvinas Appoints Jared Freedberg as General CounselNASDAQ:ARVNArvinas Inc
2024/01/1706:03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ARVNArvinas Inc
2024/01/0906:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARVNArvinas Inc
2024/01/0821:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
2023/12/0823:16Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:ARVNArvinas Inc
2023/12/0621:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARVNArvinas Inc
2023/12/0612:52GlobeNewswire Inc.Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development ProgramNASDAQ:ARVNArvinas Inc
 검색 관련기사 보기:NASDAQ:ARVN